tbuckley/cabot-search huggingface dataset:
Sixty-six consecutive cases of neuroendocrine tumor treated with somatostatin analogues: A 20-year single-center experience.
Authors: Theodoros Savvoukidis, Giuliano Ramadori
Journal: Journal of Clinical Oncology (2012)

374 Background: Neuroendocrine tumours (NET) arise from enterochromaffine and related cells found in epithelial organs throughout the body. Hormone related symptoms in neuroendocrine tumours are well treated with somatostatin analogues. Previous experience has demonstrated some antiproliferative activity of somatostatin analogues in the treatment of NET. Methods: In the last 20 years 66 patients with histologically proven NET were treated: primaries in small bowel (27), pancreas (16), rectum (9), appendix (5), lung (3), unknown (3), extra- adrenal abdominal paragangliomas (2) and stomach (1). The mean age of first diagnosis was 56 years. All of them received somatostatin analogues in long acting depot administration (or combination interferon/somatostatin analogues) for a minimum period of two months and a maximum of 139 months. Somatostatin therapy was started in patients with endocrine-active tumours immediately after the diagnosis and in patients with endocrine-inactive tumours after an observation time of 3 months without therapy if progress was observed. Tumor size was assessed every 3 months after begin of therapy. Results: Best responses were a stable disease in 46 of 66 patients (70%) and a partial remission in 2 (3%). Nineteen of 66 patients (27%) showed progress. The responses achieved were in small bowel 20/27; pancreas 13/16; rectum 7/9; pancreas 7/9 and lung 2/3. The median duration of response was 34 months (range 3-139). Conclusions: Our results document that treatment with somatostatin analogues prolongs time to progression in NET. Stabilisation of tumour mass itself is a relevant outcome for patients with NET. The benefit of somatostin analogues is indipendent to use of chemotherapy. Because of its efficacy and the good tolerability somatostatin analogues can be considered a first line treatment option.
In Brief
Journal: Nature reviews. Immunology (2005)

This study provides another explanation for the proinflammatory, T-helper-1-cell-inducing effects on CD4 + T cells of interleukin-12 (IL-12) produced by myeloid cells.CD4 + T cells can escape suppression mediated by CD4 + CD25 + regulatory T (T Reg ) cells in in vitro co-cultures through IL-12mediated support of activation, proliferation and cytokine production.This effect was not reproduced by the related family member IL-23 or by indirect effects on interferon-γ production, and it required expression of the IL-12 receptor by the effector T cells but not by the T Reg cells.The authors suggest that, in an inflamed microenvironment, IL-12 blocks immunoregulation by T Reg cells to allow an effective immune response.
Relevance of epidermal growth factor receptor kinase activity in a model of cholestatic liver injury
Authors: Nerea Lazcanoiturburu, Laura Almalé, Rebeca Méndez, Annalisa Addante, César Roncero, Paloma Bragado, Adoración Martínez-Palacián, Maria Garcia-Bravo, Julián Sanz, Jose Segovia, Isabel Fabregat, Blanca Herrera, Aranzazu Sanchez
Journal: Journal of Hepatology (2020)
Incorrect Dose in Figure
Authors: Mary-Claire King, Amnon Lahad, Ephrat Levy-Lahad
Journal: JAMA (2015)

Mikhail Kosiborod, MD; Henrik S. Rasmussen, MD, PhD; Philip Lavin, PhD; Wajeh Y. Qunibi, MD; Bruce Spinowitz, MD; David Packham, MD; Simon D. Roger, MD; Alex Yang, MD; Edgar Lerma, MD; Bhupinder Singh, MD
湿疹表型的环境和遗传风险因素
Authors: C. Hu, L. Duijts, N.S. Erler, N.J. Elbert, C. Piketty, V. Bourdès, S. Blanchet‐Réthoré, J.C. Jongste, S.G.M.A. Pasmans, J.F. Felix, T. Nijsten
Journal: British Journal of Dermatology (2019)

湿疹是一种瘙痒性皮肤病,影响全世界多达 25% 儿童,发病时间(开始的时间)和持续性(持续多久)是可变化的。需要更详细地定义湿疹类型(即表型),从而更好预测各类型的自然过程和了解其特定基础风险因素。籍此可能预防湿疹的发生和恶化。 在一个由 5297 名多种族儿童组成的基于人群的荷兰分组中,在考虑发病年龄和出生到 10 岁湿疹过程情况下,根据各湿疹表型概率鉴定出了 5 个湿疹表型。鉴定出的湿疹表型包括从未 (76%)、早发一过性 (8%)、中期一过性 (6%)、迟发一过性 (8%)和持续性湿疹 (2%)。 早发、中期和迟发一过性湿疹儿童分别在 2 岁前、2 岁左右和 5 岁左右发生湿疹的概率高,之后湿疹逐渐消失。持续性湿疹儿童从出生到 10 岁期间发生湿疹的概率高。 这一湿疹表型模型似乎适用于不断全球化世界中的多种族人群。之前明确的湿疹风险因素(包括社会经济、生活方式或与皮肤屏障缺陷和免疫系统相关的遗传学因素)在不同表型中的差异程度有限。 早发一过性湿疹只在男性中最常见。迟发一过性或持续性湿疹儿童在亚洲和非洲种族中更常见。因此,性别和种族对于预测目的来说可能有帮助。需要更多研究,最好是采用“无假设方法”的研究,来确定形成湿疹表型的其他可能预测因素,从而改善湿疹的管理和预防策略。
Monitoring Environmental Disease—United States, 1997
Journal: JAMA (1998)

One of the national health objectives for 2000 (HP2000) is to establish and monitor nonoccupational "sentinel" environmental diseases, including asthma, heatstroke, hypothermia, heavy metal poisoning, pesticide poisoning, carbon monoxide poisoning, acute chemical poisoning, and methemoglobinemia, in at least 35 states (baseline: 0 states in 1990) (objective 11.16). To assess progress toward this objective, the Council of State and Territorial Epidemiologists (CSTE), the Association of Schools of Public Health, and CDC conducted a telephone survey of environmental epidemiologists in each of the 50 states, the District of Columbia, and Puerto Rico during June-August 1997. This report summarizes the results of that survey, which indicate that progress is being made toward the HP2000 objective.
During Development, 17a-Estradiol Is a Potent Estrogen and Carcinogen
Authors: Richard A. Hajek, Audra D. Robertson, Dennis A. Johnston, Nguyen T. Van, Robert K. Tcholakian, Laura A. Wagner, Claudio J. Conti, Marvin L. Meistrich, Nancy Contreras, Creighton L. Edwards, Lovell A. Jones
Journal: Environmental Health Perspectives (1997)

Neonatal administration of estradiol-1 7,B (E2-1 7f) increases the nuclear DNA content in the mouse reproductive tract.Similar responses have been demonstrated for synthetic estrogens such as diethylstilbestrol.One of the questions raised regarding environmental estrogens such as organochlorines is whether they are potent enough to result in abnormal changes such as those demonstrated by both natural and synthetic estrogens.To test this hypothesis, female BALB/c mice were treated neonatally (days 1-5) with either E2-1 7p or estradiol-1 7a (E2-1 7a), an inactive stereoisomer in adult reproductive tissues.We also proposed whether neonatal administration of (E2-17a) was tumorigenic and whether the effects were age dependent.To answer these questions, one set each of 10-day-old treated and control mice received short-term secondary administration of E2-170, E2-17a, or cholesterol.Cervicovaginal tracts from intact BALB/c mice were examined histologically and by flow cytometry at 70 days of age and by histology alone at 18 to 22 months of age.The results include several important findings: a) like E2-1 7p, neonatal E2-1 7a treatment induced persistent vaginal cornification, hypospadias, vaginal concretions, and hyperproliferation in nearly 100% of the animals regardless of the secondary treatment for most groups; b) neonatal E2-177a treatment increased the nuclear DNA content of cervicovaginal epithelium at one-half both the level (mean DNA index of 1.02 vs 1.04) and incidence (22 vs 46% of the animals) of E2-170; c) short-term secondary treatment with E2-17a, unlike E2-170, did not significantly augment the increase in DNA content (13% for E2-1 7a vs 37 and 56% for control and E2-1 71, respectively); and d) neonatal administration with E2-1 7a induced adenosquamous tumors in the reproductive tract in 25% of the animals.Therefore, the biological effects (estrogenic potency) of E21 7a may be age dependent.
Patient's Doing Fine! Know Your Doctor and Your Hospital
Journal: JAMA (1952)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
TOMOX compared to FOLFOX4 as first-line treatment in patients (pts) with advanced colorectal cancer (ACRC): Preliminary results of a multicenter randomized phase II trial
Authors: C. Grávalos, C. García-Girón, A. I. León, A. Salud, B. Esteban, I. Sevilla, J. Maurel, A. Murias, E. García-Rico, H. G. Cortés-Funes
Journal: Journal of Clinical Oncology (2004)

3599 Background: FOLFOX-4 has shown to be safe and active (response rate (RR): 50.7%) in chemotherapy-naive treated pts (De Gramont, JCO 2000). TOMOX is a promising new combination with RR 61.9% (Douillard J, ASCO 2000). We designed a randomized phase II trial to compare the activity (RR), tolerance, time to progression (TTP), overall survival (OS), quality of life and day-hospital frequentation between the two arms. Methods: From Jan/2002 to Nov/2003, 166 pts without previous treatment for ACRC have been randomized to arm A: FOLFOX-4 or arm B: TOMOX (raltitrexed 3 mg/m2 + OXA 130 mg/m2 d1, q3w). Results: Ninety-five pts are evaluable for efficacy and toxicity. 43/95 pts are still receiving treatment. Baseline data: 56% men; median age 64; ECOG 0/1: 50/45; 38% rectal cancer; 87.4% pts had previous primary tumor resection . Median number cycles were: 6.5 (1–16) in A; 5 (1–13) in B. Efficacy: The RR were: TOMOX 39.1% (95%CI 25–54.6%) and FOLFOX-4: 49% (95%CI 34.4–64.6%). The TTP and OS were similar. Tolerance: G3–4 neutropenia was more frequent in FOLFOX-4 (39.1% vs 2%, p < 0.0001). Transaminitis was more higher with TOMOX (2.1% vs 22.4%, p= 0.003). Compliance: Patients under TOMOX regimen have less frequency attendant at day-hospital for chemotherapy administration (median 12 days vs 6, p < 0.0001). Conclusions: Our preliminary results suggest that FOLFOX4 and TOMOX, as administered in this trial, show similar high activity (RR, TTP and OS) as first line treatment. The grade 3–4 toxicity profile varies depending on the arm: neutropenia is more common in FOLFOX4 and transaminitis in TOMOX. No significant financial relationships to disclose.
A Piece of My Mind
Journal: JAMA (1981)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Senile macular degeneration: an artist's view
Authors: R. D. Sperduto
Journal: JAMA (1983)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Allelic association of human dopamine D2 receptor gene in alcoholism
Authors: K. Blum
Journal: JAMA (1990)

In a blinded experiment, we report the first allelic association of the dopamine D<sub>2</sub>receptor gene in alcoholism. From 70 brain samples of alcoholics and nonalcoholics, DNA was digested with restriction endonucleases and probed with a clone that contained the entire 3' coding exon, the polyadenylation signal, and approximately 16.4 kilobases of noncoding 3' sequence of the human dopamine D<sub>2</sub>receptor gene (λhD2G1). In the present samples, the presence of A1 allele of the dopamine D<sub>2</sub>receptor gene correctly classified 77% of alcoholics, and its absence classified 72% of nonalcoholics. The polymorphic pattern of this receptor gene suggests that a gene that confers susceptibility to at least one form of alcoholism is located on the q22-q23 region of chromosome 11. (<i>JAMA</i>. 1990;263:2055-2060)
Journal of Clinical Investigation, Boston
Journal: JAMA (1964)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
3-D echocardiography of the aortic valve is superior to 2-D echocardiography when compared to operative anatomy Zheng Liu, Wei Lau, Thippeswamy H. Murthy, Peng Li, Farzan Rajput, William Armstrong, Mani Vannan. University of Michigan Health System, Ann Arbor, MI
Journal: Journal of the American College of Cardiology (2001)
Errors in Subtitle, Group Author Byline, Key Points, and Methods
Authors: Theodore Satterthwaite, Raquel Gur
Journal: JAMA Psychiatry (2017)

the conclusions of this study.Thus, after correcting this error, our original conclusions, as stated in the Abstract and Discussion, remain unchanged.Specifically, we continue to find that volume is reduced in youths with psychosis spectrum symptoms in a pattern distributed widely across the gray matter of the brain, including medial temporal lobe volume loss that relates selectively to the burden of psychosis spectrum symptoms.These findings continue to support our broadest and most important conclusion, namely that structural brain abnormalities commonly reported in adults with psychosis are present early in life in youths with psychosis spectrum symptoms.
VIENNA
Journal: JAMA (1922)

<h3>Convention of the German Gynecologic Society at Innsbruck</h3> The third Austrian university town, Innsbruck, was selected by the German Gynecologic Society as a meeting place for its yearly convention at this time. Owing to the pressure of time—it lasted only three days, June 8-11—and to the hardships of travel in central Europe, little attention was paid to purely social activities, more earnest work being the aim. Surgeons from northern Europe, Switzerland, Japan, Jugoslavia and America were present. More than 208 papers were presented, exceeding the number read at any previous meeting of the society. The young men were in the majority at the convention, because the older men were unfitted for the hardships attending the journey and the overcrowded conditions of the city. Thus, their ripe opinion had to be foregone. The papers were divided under four heads: treatment of cancer by actinic methods (radium or roentgen rays), the mechanism
Announcements
Authors: Catherine Lein, Joseph C. Gardiner, Annemarie Hodges, Francesca C. Dwamena, John Coffey, Clare Collins, Hans-Jürgen Rumpf, Werner Löntz, Susanne Uesseler, Dan Hasson, Bengt Arnetz, Lena Jelveus, Bo Edelstam, Fotios Anagnostopoulos, Gregoris Vaslamatzis, Marios Markidis, Giovanni A. Fava, Richard Balon, Elie Korban, Mohammed Kanj, Robert Haddad, Judith S. Lyles, Robert C. Smith, Peter R. Mansfield, Fiona Denton, Louise Sharpe, Leslie Schrieber, Steinar Lorentzen, Per Høglend, Staffan Svensson
Journal: Psychotherapy and Psychosomatics (2003)
Just Words
Authors: Alexander Gode
Journal: JAMA (1966)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Resident Burnout
Authors: Niku K Thomas
Journal: JAMA (2004)

Intense work demands, limited control, and a high degree of work-home interference abound in residency training programs and should strongly predispose resident physicians to burnout as they do other health care professionals. This article reviews studies in the medical literature that address the level of burnout and associated personal and work factors, health and performance issues, and resources and interventions in residents. MEDLINE and PubMed databases were searched for peer-reviewed, English-language studies reporting primary data on burnout or dimensions of burnout among residents, published between 1983 and 2004, using combinations of the Medical Subject Heading terms burnout, professional, emotional exhaustion, cynicism, depersonalization and internship and residency, housestaff, intern, resident, or physicians in training and by examining reference lists of retrieved articles for relevant studies. A total of 15 heterogeneous articles on resident burnout were thus identified. The studies suggest that burnout levels are high among residents and may be associated with depression and problematic patient care. However, currently available data are insufficient to identify causal relationships and do not support using demographic or personality characteristics to identify at-risk residents. Moreover, given the heterogeneous nature and limitations of the available studies, as well as the importance of having rigorous data to understand and prevent resident burnout, large, prospective studies are needed.
Update: Recommendations From the Advisory Committee on Immunization Practices (ACIP) Regarding Administration of Combination MMRV Vaccine
Journal: JAMA (2008)

On February 27, 2008, new information was presented to the Advisory Committee on Immunization Practices (ACIP) regarding the risk for febrile seizures among children aged 12-23 months after administration of the combination measles, mumps, rubella, and varicella (MMRV) vaccine (ProQuad, Merck & Co., Inc., Whitehouse Station, New Jersey). This report summarizes current knowledge regarding the risk for febrile seizures after MMRV vaccination and presents updated ACIP recommendations that were issued after presentation of the new information. These updated recommendations remove ACIP's previous preference for administering combination MMRV vaccine over separate injections of equivalent component vaccines (i.e., measles, mumps, and rubella [MMR] vaccine and varicella vaccine).
Investigators Report on Latest Developments in Clinical Research
Journal: JAMA (1964)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal